{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:31Z","timestamp":1761870691910,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,8,2]],"date-time":"2015-08-02T00:00:00Z","timestamp":1438473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ministry of Science and Technology","award":["P3-0321"],"award-info":[{"award-number":["P3-0321"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.clml.2015.07.631","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T15:09:06Z","timestamp":1438787346000},"page":"586-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of Treatment in Slovene Follicular Lymphoma Patients"],"prefix":"10.1016","volume":"15","author":[{"given":"Tanja","family":"Ju\u017eni\u010d \u0160etina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bor\u0161tnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Jezer\u0161ek Novakovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.07.631_bib1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.07.631_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.07.631_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.631_bib6","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib7","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib8","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.631_bib9","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.631_bib10","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly\u00a0\u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.631_bib11","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib12","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.631_bib13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib14","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.631_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.07.631_bib16","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib17","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"suppl 3","key":"10.1016\/j.clml.2015.07.631_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"year":"2013","series-title":"Cancer in Slovenia, 2010","author":"Primic \u017dakelj","key":"10.1016\/j.clml.2015.07.631_bib20"},{"key":"10.1016\/j.clml.2015.07.631_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2015.07.631_bib23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib24","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.07.631_bib26","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiaina Linfoni","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib27","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.631_bib28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2015.07.631_bib29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/annonc\/mdm511","article-title":"The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma","volume":"19","author":"Overman","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.07.631_bib30","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:39Z","timestamp":1761870399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015010630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S2152265015010630"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.631","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Treatment in Slovene Follicular Lymphoma Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}